Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNMBiotechnology
-$0.39 today
- Market cap
- $326.66M
- Beta
- 0.89
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$1.57
Volume 0.20M
Average 0.26M
Dividends
Contineum Therapeutics, Inc. Class A Common Stock dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does Contineum Therapeutics, Inc. Class A Common Stock compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX | $1.39B | 0.00% | $0.00 | 0.00% | 0.00% |
GH Research PLC NASDAQ:GHRS | $1.31B | 0.00% | $0.00 | 0.00% | 0.00% |
Rapport Therapeutics, Inc. Common Stock NASDAQ:RAPP | $1.25B | 0.00% | $0.00 | 0.00% | 0.00% |
Alto Neuroscience, Inc. NYSE:ANRO | $1.18B | 0.00% | $0.00 | 0.00% | 0.02% |
Seaport Therapeutics, Inc. Common Stock NASDAQ:SPTX | $1.07B | — | $0.00 | — | 0.00% |
MapLight Therapeutics, Inc. NASDAQ:MPLT | $308.98M | 0.00% | $0.00 | 0.00% | 0.00% |
AC Immune S.A. NASDAQ:ACIU | $216.78M | 0.00% | $0.00 | 0.00% | 0.00% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $80.59M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about CTNM's dividend, answered from reported figures.
Does CTNM stock pay dividends?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is CTNM's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.